Prediction of In Vivo Pharmacokinetic Parameters and Time-Exposure Curves in Rats Using Machine Learning from the Chemical Structure.

Journal: Molecular pharmaceutics
PMID:

Abstract

Animal pharmacokinetic (PK) data as well as human and animal in vitro systems are utilized in drug discovery to define the rate and route of drug elimination. Accurate prediction and mechanistic understanding of drug clearance and disposition in animals provide a degree of confidence for extrapolation to humans. In addition, prediction of in vivo properties can be used to improve design during drug discovery, help select compounds with better properties, and reduce the number of in vivo experiments. In this study, we generated machine learning models able to predict rat in vivo PK parameters and concentration-time PK profiles based on the molecular chemical structure and either measured or predicted in vitro parameters. The models were trained on internal in vivo rat PK data for over 3000 diverse compounds from multiple projects and therapeutic areas, and the predicted endpoints include clearance and oral bioavailability. We compared the performance of various traditional machine learning algorithms and deep learning approaches, including graph convolutional neural networks. The best models for PK parameters achieved = 0.63 [root mean squared error (RMSE) = 0.26] for clearance and = 0.55 (RMSE = 0.46) for bioavailability. The models provide a fast and cost-efficient way to guide the design of molecules with optimal PK profiles, to enable the prediction of virtual compounds at the point of design, and to drive prioritization of compounds for in vivo assays.

Authors

  • Olga Obrezanova
    Data Science and AI, Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.
  • Anton Martinsson
    Data Science and AI, Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg SE-43183, Sweden.
  • Tom Whitehead
    Intellegens Ltd., Eagle Labs, Cambridge CB4 3AZ, U.K.
  • Samar Mahmoud
    Optibrium Limited, Cambridge, UK. samar@optibrium.com.
  • Andreas Bender
    Centre for Molecular Informatics, Yusuf Hamied Department of Chemistry, University of Cambridge UK ab454@cam.ac.uk.
  • Filip Miljković
    Department of Life Science Informatics, B-IT, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität, Endenicher Allee 19c, D-53115 Bonn, Germany.
  • Piotr Grabowski
    Bioanalytics, Institute of Biotechnology, Technische Universität Berlin, 13355 Berlin, Germany.
  • Ben Irwin
    Optibrium Ltd., Cambridge Innovation Park, Cambridge CB25 9PB, U.K.
  • Ioana Oprisiu
    Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg SE-43183, Sweden.
  • Gareth Conduit
    Intellegens Limited, Cambridge, UK.
  • Matthew Segall
    Optibrium Limited, Cambridge, UK.
  • Graham F Smith
    Imaging & Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. graham.smith@astrazeneca.com.
  • Beth Williamson
    Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology, R&D, AstraZeneca, Cambridge CB10 1XL, U.K.
  • Susanne Winiwarter
    Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceutical R&D, AstraZeneca, Gothenburg SE-43183, Sweden.
  • Nigel Greene
    Data Science and AI, Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.